加载中
NASDAQHealthcareBiotechnology
最新数据
US$7.115
−US$0.135 · -1.86%
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
常规交易时段
US$7.1182
−US$0.1318 · -1.82%
盘中时间采用ET。市场数据可能有所延迟。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日内区间
当前US$7.1182
52周区间
当前US$7.1182
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
72
低估
情绪
54
多空交织
风险
50
风险偏高
动量
63
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
日内区间
当前US$7.1182
52周区间
当前US$7.1182
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.75亿 USD | 5525.2万 USD | 68.2万 USD | — | — |
| 销货成本 | 2259.9万 USD | 797.3万 USD | 16.7万 USD | 62万 USD | 52.1万 USD |
| 毛利 | 1.53亿 USD | 4727.9万 USD | 51.5万 USD | −62万 USD | −52.1万 USD |
| 研究与开发 | 3278万 USD | 3408.2万 USD | 4989.9万 USD | 7144.1万 USD | 7233.8万 USD |
| 销售、一般及管理费用 | 2.8亿 USD | 2.91亿 USD | 1.18亿 USD | 1亿 USD | 6222.1万 USD |
| 营业费用 | 3.12亿 USD | 3.25亿 USD | 1.68亿 USD | 1.72亿 USD | 1.35亿 USD |
| 利息收入 | 704.4万 USD | 1515.8万 USD | 787.6万 USD | 213.2万 USD | 4.1万 USD |
| 利息支出 | 6811.5万 USD | 7200.9万 USD | 4196.8万 USD | 2730.5万 USD | 678.8万 USD |
| 折旧和摊销 | 63.3万 USD | 79.5万 USD | 57.5万 USD | 62万 USD | 52.1万 USD |
| 营业利润 | −1.6亿 USD | −2.77亿 USD | −1.67亿 USD | −1.72亿 USD | −1.35亿 USD |
| 净利润 | −2.21亿 USD | −3.34亿 USD | −2.02亿 USD | −1.98亿 USD | −1.44亿 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1921.34万0.00%2.3万亿 USD0.03%US$381.43-0.13%
iShares Russell 2000 ETFIWM940.12万0.01%787.4亿 USD0.19%US$277.81-0.41%
Vanguard Extended Market ETFVXF568.32万0.01%954亿 USD0.05%US$233.46-0.66%
State Street SPDR S&P Pharmaceuticals ETFXPH524.41万1.14%4.62亿 USD0.35%US$64.04-0.94%
iShares Biotechnology ETFIBB287.11万0.03%108.2亿 USD0.44%US$204.12-1.15%
Vanguard Russell 2000 ETFVTWO270.51万0.01%180亿 USD0.06%US$112.22-0.39%
Schwab U.S. Small-Cap ETFSCHA217.67万0.01%218.24亿 USD0.03%US$32.655-0.41%
Simplify Propel Opportunities ETFSURI180.72万2.38%7606.44万 USD2.82%US$17.18+0.76%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
